Aurinia Pharmaceuticals (IKAP) Stock Price & Analysis
IKAP Stock Chart & Stats
- Day’s Range
- EUR 14.82 - EUR 15.17
- 52-Week Range
- EUR 10.27 - EUR 16.40
- Previous Close
- EUR 15.37
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 1.98B
- Enterprise Value
- EUR 1.89B
- Total Cash (Recent Filing)
- EUR 486.88M
- Total Debt (Recent Filing)
- EUR 58.66M
- Price to Earnings (P/E)
- 7.0
- Beta
- 0.17
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- 0.19
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Extended U.S. Exclusivity
The Teva settlement supports continued U.S. exclusivity for voclosporin for roughly another decade, protecting Aurinia’s principal commercial franchise from this generic challenge. That legal outcome can sustain pricing power, prescription economics, and cash generation while the company develops its longer-term strategy.
Strong Cash Generation
Strong operating and free cash flow closely tracking reported earnings indicates that current profitability is converting into internally generated funding. This improves financial resilience, supports commercial investment without heavy borrowing, and gives Aurinia greater flexibility to allocate capital across its autoimmune portfolio.
Commercial Growth
Aurinia’s revenue growth and recent commercial scale demonstrate increasing adoption of its marketed therapy rather than a purely development-stage business model. Continued top-line expansion can broaden the earnings base, improve operating leverage, and reinforce the company’s position in lupus nephritis treatment.
Bears Say
Single-Product Concentration
Reliance on LUPKYNIS as the primary commercial product concentrates revenue and operating performance in one therapy. Any disruption to demand, reimbursement, prescribing, adherence, or the product’s commercial position would therefore have an outsized effect on Aurinia’s growth and cash-generation outlook.
Profitability Volatility
The recent profitability inflection is encouraging, but the preceding multiyear losses show that earnings power has not yet been demonstrated consistently across cycles. This history makes future margins and cash generation less predictable than those of a mature, diversified pharmaceutical company.
Ongoing Generic Litigation
Although the Teva settlement is favorable, multiple other generic challenges remain active and continue to require legal defense. Adverse outcomes or delays in these proceedings could weaken the durability of voclosporin exclusivity, increasing uncertainty around the product’s long-term revenue base.
IKAP FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
What is Aurinia Pharmaceuticals’s market cap?
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
How were Aurinia Pharmaceuticals’s earnings last quarter?
Is Aurinia Pharmaceuticals overvalued?
Does Aurinia Pharmaceuticals pay dividends?
What is Aurinia Pharmaceuticals’s EPS estimate?
How many shares outstanding does Aurinia Pharmaceuticals have?
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Aurinia Pharmaceuticals Stock Smart Score
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kevin C. Tang
- Employees
- 128
- Website
- www.auriniapharma.com
- Address
- #140, 14315 – 118 Avenue, Edmonton, AB, T5L 4S6, CA
Aurinia Pharmaceuticals (IKAP) Earnings & Revenues
IKAP Earnings Call
Earnings Call SentimentPositive
The call highlights robust commercial momentum for LUPKYNIS with double-digit top-line growth, materially improved cash generation, a strong balance sheet and share repurchases. Management provided constructive 2026 guidance and disclosed promising early clinical results for aritinercept. Offsetting these positives are a significant one-time tax benefit that materially boosted reported net income, termination of a pediatric study (creating regulatory follow-up risk), emerging competition (Gazyva), limited near-term transparency on quarterly performance, and early-stage development uncertainties (ADAs). Overall, the positives—sustained product revenue growth, strong cash flow, and advancing pipeline—outweigh the headwinds, though some risks remain.
View all DE:IKAP earnings summariesIKAP Net sales Breakdown
- 90.00% U.S.
- 10.00% Japan
IKAP Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 5 | 6 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 8 | 0 | 4 |